These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Why have we failed to achieve neuroprotection in Parkinson's disease? Olanow CW; Kieburtz K; Schapira AH Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580 [TBL] [Abstract][Full Text] [Related]
3. Designing neuroprotection trials in Parkinson's disease. Kieburtz K Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102 [TBL] [Abstract][Full Text] [Related]
4. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Naoi M; Maruyama W Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610 [TBL] [Abstract][Full Text] [Related]
5. Neuroprotection for Parkinson's disease: prospects and promises. Olanow CW; Schapira AH; Agid Y Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093 [No Abstract] [Full Text] [Related]
14. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Stocchi F Int J Clin Pract; 2006 Feb; 60(2):215-21. PubMed ID: 16451296 [TBL] [Abstract][Full Text] [Related]
17. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment. LeWitt PA J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399 [TBL] [Abstract][Full Text] [Related]
18. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. Löhle M; Reichmann H J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974 [TBL] [Abstract][Full Text] [Related]
19. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Mandel S; Weinreb O; Amit T; Youdim MB Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677 [TBL] [Abstract][Full Text] [Related]